Cerenome is trading 6.4% higher at $1.99 after announcing a September 30 business update call focused on CNSide commercial progress.
- Topics include third-party billing, market access, commercial-team expansion, and broader diagnostic testing.
- Management described recent developments as positive and said it would discuss progress toward 2026 goals and plans to expand the business.